Top journals
Frequent coauthors
- Apaolaza I 1
- Geldhof A 1
- Schaible T 1
2019
On August 24, 1998, Remicade® (infliximab), the first tumor necrosis factor-α (TNF) inhibitor, received its initial marketing approval from the US Food and Drug Administration for the treatment of Crohn's disease. Subsequently, Remicade was…